(2) Overcoming DC dysfunction—given that endogenous DCs in AML are often impaired, engineered CAR‐DCs with activation domains (e.g., CD40 or 4‐1BB) can achieve rapid maturation upon CAR signalling and resist TME suppression more effectively than cDC vaccines. The gene discussed is CD40; the disease is acute myeloid leukemia.